Table 2 Patients who withdrew from the study by primary reason.

	Etanercept 50 mg once weekly (n = 155)	Etanercept 25 mg twice weekly (n = 150)	Placebo (n = 51)
All reasons	14 (9.0)	14 (9.3)	7 (13.7)
Adverse events	6 (3.9)	8 (5.3)	0 (0.0)
Protocol violation	5 (3.2)	2 (1.3)	1 (2.0)
Patient request	1 (0.6)	1 (0.7)	2 (3.9)
Lack of efficacy	2 (1.3)	3 (2.0)	3 (5.9)
Other	0 (0)	0 (0)	1 (2.0)

Values are n (%).